DXCM · Plain-English company overview
A stock is a share of ownership in a company. Owning one means you own a small piece of that business.
In the company's own words, from Item 1 (Business) of its latest annual report (Form 10-K) filed with the SEC on 2026-02-12.
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.
We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. In August 2024, we launched Stelo, our biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.
Read the full 10-K on SEC.gov →
An earnings release is a company's quarterly report of how much money it made. Analysts predict these numbers ahead of time, and the actual results are compared against those predictions.
In the most recent quarter (2026-06-30), Dexcom reported earnings of $0.7 per share. Analysts expected $0.6229 per share, so the company beat expectations.
Zelothorn provides plain-English summaries drawn from official SEC filings for educational purposes only. It is not financial advice and does not recommend buying or selling any security.